MolDX: EndoPredict® Breast Cancer Gene Expression Test

The EndoPredict test is covered for post‑menopausal women with early‑stage (T1‑T3, N0‑N1) ER‑positive, HER2‑negative breast cancer when adjuvant endocrine therapy is being considered. The test is intended to assess 10‑year distant recurrence risk to inform whether a patient with low risk may safely omit adjuvant chemotherapy. Coverage excludes patients who do not meet the listed clinical criteria (e.g., pre‑menopausal status, ER‑negative or HER2‑positive disease, or more advanced TNM stage), which require manual review for specific cases.

"Coverage is provided for post‑menopausal women with early‑stage invasive breast cancer (TNM T1‑T3, N0‑N1) that is estrogen receptor (ER) positive and HER2‑negative when adjuvant endocrine therapy i..."

Sign up to see full coverage criteria, indications, and limitations.